KDC-MN-202 – Kodiac biolabs

Plain-language summaryIntrigue 67 / 100

Sertraline (Zoloft) is one of the most widely prescribed psychiatric medications on the planet. Pfizer brought it to market in 1991 as a follow-on to Prozac with a slightly different shape and a slightly different side-effect profile. The main action is the standard SSRI move: block serotonin from being recycled back into the cell that fired it. A small bonus is mild blockade of the dopamine pump, which a few researchers credit with the somewhat brighter subjective profile some patients report compared to other SSRIs. Approved for depression, OCD, panic, PTSD, social anxiety, and premenstrual mood disorder. Generally considered first-line and reasonably well tolerated. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Clinically dominant reference SSRI with exhausted novelty and modest bench utility as a comparator compound

Look, sertraline is probably the most clinically well-validated compound in our library, and thats exactly the problem. When a molecule has been prescribed to tens of millions of people across six approved indications since 1991, the bench science has long since moved on. We’re not here to revisit what we already know about SERT inhibition. Pfizer’s chemists synthesized this in 1977; the basic pharmacology was settled before most active investigators were in graduate school.

The mechanism is nanomolar SERT inhibition (Ki approximately 0.3 nM) with a minor DAT component (Ki approximately 25 nM) that distinguishes it somewhat from the rest of the SSRI class. We think the DAT angle is genuinely the most scientifically interesting thing about sertraline, and it’s mostly a footnote. The 5-HTTLPR literature tried to personalize SSRI prescribing for decades and largely failed; the monoamine hypothesis has taken its share of hits; and anything new you want to ask about SERT biology has better, more selective probes available today. The research conversation has moved toward network-level antidepressant mechanisms, rapid-acting approaches, and psychoplastogens that make single-target reuptake inhibition look like a solved problem.

Where sertraline does hold genuine bench value is as a reference standard. The dichlorophenyl moiety is a frequently-appearing structural feature in SSRI SAR programs, and if you’re running SERT binding assays sertraline is a logical comparator. It’s also a well-characterized positive control in rodent FST and TST models of depression and anxiety, which matters when you want a known-good anchor alongside whatever experimental compound you’re actually studying. That’s real utility, but it’s the utility of a ruler, not the utility of what you’re measuring.

The evidence and translational scores are, honestly, among the highest in the library. Multiple phase 3 RCTs, regulatory approvals across major jurisdictions, replicated over three decades. The irony is that this is precisely why sertraline scores poorly on novelty and mechanism: the literature is exhausted, not exciting. A serious investigator doesn’t wake up thinking they should study sertraline. They wake up thinking they need sertraline as a control condition.

Sourcing is trivial, stability is excellent, the CYP interaction profile is thoroughly mapped (2D6 inhibition present but weaker than fluoxetine or paroxetine), and there are no surprises in handling. None of that makes it a compelling primary research target; it makes it convenient. We score it at 45 because the bench reference value and the sterling clinical record pull it above the floor, but this is not where a serious research program directs its primary attention. Use it as the comparator, not the subject.

Novelty: 18
Mechanism promise: 22
In-category differentiation: 28
Evidence quality: 88
Translational signal: 82
Research bench value: 55

Rationale Stellar evidence and translational scores reflect decades of replicated phase 3 data across six indications, but these are entirely offset by near-zero novelty and mechanism interest; sertraline’s bench value is real but confined to reference-standard roles in SERT binding studies and animal model controls. No structural cap applies.

Selective serotonin reuptake inhibitor

A naphthylamine SSRI with mild dopamine reuptake inhibition; one of the most prescribed psychiatric medications worldwide.

Abstract

Sertraline ((1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine; CAS 79617-96-2; molecular formula C17H17Cl2N; molecular weight 306.23) is a tetrahydronaphthalene SSRI synthesized at Pfizer in 1977 and approved by the FDA in 1991 under the trade name Zoloft. SERT affinity is nanomolar (Ki approximately 0.3 nM); the compound exhibits weak dopamine transporter inhibition (Ki approximately 25 nM) that is unusual within the SSRI class and may contribute to a subtly different subjective profile. Plasma half-life is 22 to 36 hours; the principal metabolite N-desmethylsertraline is pharmacologically active but with reduced SERT affinity. Hepatic metabolism is via CYP2B6, CYP2C19, CYP2D6, and CYP3A4; clinically relevant CYP2D6 inhibition exists but is weaker than fluoxetine or paroxetine. Approved indications include major depressive disorder, OCD, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric disorder. Used as a reference compound in SERT binding studies and animal models of depression and anxiety; the dichlorophenyl moiety is a target structural feature in numerous SSRI structure-activity relationship studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-202Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-202

Sertraline

Abstract

Read the full monograph